

SAFETY DATA SHEET

Cat# 1550, Cisplatin

REV SDS DATE: April 15, 2020

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: Cisplatin
PRODUCT CODES: Cat# 1550-100, -1000
RESTRICTIONS ON USE: For laboratory research purposes. Not for drug or household use.
MANUFACTURER: BioVision, Inc.
ADDRESS: 155 S. Milpitas Boulevard, Milpitas, CA 95035
EMERGENCY PHONE: 858-373-8066
CHEMTREC PHONE:
OTHER CALLS: 408-493-1800
FAX PHONE: 408-493-1801

SECTION 2: COMPOSITION/INFORMATION ON INGREDIENTS

Component	Description	Volume	Safety Information
Cisplatin	Solid	1550-100: 100 mg 1550-1000: 1 g	See below

SECTION 3: HAZARDS IDENTIFICATION

Product Name/Chemical Name	CAS Number	EC-No.	MW	Chemical Formula	Concentration
Cisplatin	15663-27-1	239-733-8	300.05	Pt(NH ₃) ₂ Cl ₂	100%

Cisplatin:

Emergency Overview

OSHA Hazards: Carcinogen, Target organ effect, Highly toxic by ingestion, Irritant

Target Organs: Liver injury may occur, Kidney, Ears, Blood, Peripheral nervous system, Bone marrow, Testes, Female reproductive system

GHS Label elements, including precautionary statements

Pictogram:



Signal word: Danger
Hazard statement(s): H300 Fatal if swallowed.
H316 Causes mild skin irritation.
H318 Causes serious eye damage.
Precautionary statement(s): P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/eye protection/face protection.
P301+P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P310 Immediately call a POISON CENTER or doctor/physician.
P330 Rinse mouth.
P332+P313 If skin irritation occurs: Get medical advice/attention.
P405 Store locked up.
P501 Dispose of contents/container to an approved waste disposal plant.

HMIS Classification

Health hazard: 3

Chronic health hazard: *

Flammability: 0

Physical hazards: 0

NFPA Rating

Health Hazard: 3

Fire: 0

Reactivity Hazard: 0

Potential Health Effects

Inhalation: May be harmful if inhaled. Causes respiratory tract irritation.

Skin: May be harmful if absorbed through skin. Causes skin irritation.

Eyes: Causes eye irritation.

Ingestion: May be fatal if swallowed.

SAFETY DATA SHEET

Cat# 1550, Cisplatin

REV SDS DATE: April 15, 2020

SECTION 4: FIRST AID MEASURES

General advice: Consult a physician. Show this safety data sheet to the doctor in attendance. Move out of dangerous area.

If inhaled: If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.

In case of skin contact: Wash off with soap and plenty of water. Consult a physician.

In case of eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

If swallowed: Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.

5: FIRE-FIGHTING MEASURES

Condition of flammability: Not flammable or combustible.

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters: Wear self-contained breathing apparatus for firefighting if necessary.

Hazardous combustion products: Hazardous decomposition products formed under fire conditions— nitrogen oxides, hydrogen chloride gas.

SECTION 6: ACCIDENTAL RELEASE MEASURES

Personal precautions: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation.

Evacuate personnel to safe areas.

Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

Methods for cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

SECTION 7: HANDLING AND STORAGE

Precautions for safe handling

Avoid formation of dust and aerosols. Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Conditions for safe storage

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20 °C

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment

Respiratory protection

Where risk assessment shows air-purifying respirators are appropriate use a full-face particle respirator type N100 (US) or type P3 (EN 143) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands.

Eye protection

Face shield and safety glasses. Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).

Skin and body protection

The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace.

Hygiene measures

Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

Property	Cisplatin
Appearance:	Yellow powder
pH:	No data available
Water Solubility:	No data available
Specific Gravity (g/ml):	No data available
Boiling Point (°C):	No data available
Melting Point (°C):	270 °C (518 °F)
Flash Point (°C):	No data available
Ignition Temperature (°C):	No data available

SAFETY DATA SHEET

Cat# 1550, Cisplatin

REV SDS DATE: April 15, 2020

Density	No data available
---------	-------------------

SECTION 10: STABILITY AND REACTIVITY

Property	Cisplatin
Chemical stability	Stable under recommended storage conditions
Conditions to avoid:	No data available
Materials to avoid:	Strong oxidizing agents
Hazardous decomposition products:	Nitrogen oxides, hydrogen chloride gas

SECTION 11: TOXICOLOGICAL INFORMATION

Cisplatin:

Acute toxicity: LD50 Oral – rat – 25.8 mg/kg

Skin corrosion/irritation: no data available

Serious eye damage/eye irritation: no data available

Respiratory or skin sensitization: Prolonged or repeated exposure may cause allergic reactions in certain sensitive individuals.

Germ cell mutagenicity: no data available

Carcinogenicity:

Carcinogenicity – mouse – Intraperitoneal

Tumorigenic: Neoplastic by RTECS criteria. Skin and Appendages: Other: Tumors. Tumorigenic Effects: Uterine tumors.

Carcinogenicity – mouse – Intraperitoneal

Tumorigenic: Carcinogenic by RTECS criteria. Lungs, Thorax, or Respiration: Tumors.

This product is or contains a component that has been reported to be probably carcinogenic based on its IARC, OSHA, ACGIH, NTP, or EPA classification.

IARC: 2A – Group 2A: Probably carcinogenic to humans (Cisplatin)

ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH.

NTP: Reasonably anticipated to be a human carcinogen (Cisplatin)

OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

Reproductive toxicity: no data available

Specific target organ toxicity – single exposure (GHS): no data available

Specific target organ toxicity – repeated exposure (GHS): no data available

Aspiration hazard: no data available

Potential Health Effects

Inhalation: May be harmful if inhaled. Causes respiratory tract irritation.

Skin: May be harmful if absorbed through skin. Causes skin irritation.

Eyes: Causes eye irritation.

Ingestion: May be fatal if swallowed.

Additional information: RTECS: TP2450000

SECTION 12: ECOLOGICAL INFORMATION

Cisplatin:

Persistence and degradability: no data available

Toxicity: no data available

Bioaccumulative potential: no data available

Mobility in soil: no data available

PBT and vPvB assessment: no data available

Other adverse effects: no data available

SECTION 13: DISPOSAL CONSIDERATIONS

Product: Observe all federal, state and local environmental regulations. Contact licensed professional waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.

Contaminated packaging: Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

Cisplatin:

DOT (US): Not dangerous goods.

IMDG: Not dangerous goods.

IATA: Not dangerous goods.

SECTION 15: REGULATORY INFORMATION

SAFETY DATA SHEET

Cat# 1550, Cisplatin

REV SDS DATE: April 15, 2020

Cisplatin:

OSHA Hazards: Carcinogen, Target organ effect, Highly toxic by ingestion, Irritant

DSL Status: This product contains the following components listed on the Canadian NDSL list. All other components are on the Canadian DSL List. Cisplatin, CAS-No. 15663-27-1

SARA 302 Components: SARA 302: No chemical in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components: SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title II, Section 313.

SARA 311/312 Hazards: Acute Health Hazard, Chronic Health Hazard

Massachusetts Right To Know Components: No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know Components: Cisplatin, CAS-No. 15663-27-1, Revision Date: 1993-04-24

New Jersey Right To Know Components: Cisplatin, CAS-No. 15663-27-1, Revision Date: 1993-04-24

California Prop. 65 Components:  **WARNING:** This product can expose you to chemicals including Cisplatin, which is known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

EU regulations

Component	Risk Phrases	Safety Phrases
Cisplatin	R23/24/25, R36/37/39, R45-46	S22, S26, S36/37/39, S45, S53

SECTION 16: OTHER INFORMATION

OTHER INFORMATION:

PREPARATION INFORMATION:

DISCLAIMER:

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product. BioVision, Inc., shall not be held liable for any damage resulting from handling or from contact with the above product. See reverse side of invoice or packing slip for additional terms and conditions of sale.